Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Aleris in connection with the acquisition of Art Clinic AB
Mandate

Vinge advises Aleris in connection with the acquisition of Art Clinic AB

May 03, 2022 M&A

Vinge advises Aleris Sjukvård AB in connection with the acquisition of Art Clinic AB. Art Clinic AB operates four specialized clinics with five sub-practices in six regions in Sweden.

Aleris is one of Scandinavia’s leading healthcare provider with two million patient appointments per year and operates specialized care at over 130 locations in Sweden, Norway and Denmark. Aleris strengthens through the transaction its specialized healthcare within orthopedics, back surgery as well as aesthetic and reconstructive plastic surgery in Sweden.

Closing of the transaction is subject to applicable competition law approvals and other customary closing conditions.

Vinge’s team consisted of Christina Kokko, Samra Baytar, Olivia Belding and Elias Bohlin (M&A), Johan Wahlbom (Competition), Christoffer Nordin, Sam Fakhraie Ardekani and Max Hetta (Agreements), Emil Lindwall (Employment), Nour Makie (Banking and Finance), Karolina Fuhrman (IT/GDPR), Frida Ställborn (Real Estate) and Jessica Henning (VDR specialist).

Related

Vinge has advised Egetis Therapeutics in connection with a directed share issue

 Vinge has advised Egetis Therapeutics AB (publ) (“Egetis Therapeutics”), listed on Nasdaq Stockholm, in connection with a directed share issue whereby Egetis Therapeutics raised proceeds of approximately SEK 183 million before transaction costs.
October 06, 2025

Vinge worked with funds advised by Agilitas on the buy-out of Vivicta (previously Tietoevry Tech Services), including on the issuance of senior secured bonds and on entering into a super senior RCF

 Vinge, together with O’Melveny as lead counsel and Avance, worked with funds advised by Agilitas Private Equity LLP (“Agilitas”), the pan-European mid-market private equity firm, in their backing of Vivicta. The buy-out was previously announced on 24 March 2025 and closed on 2 September 2025.
October 03, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 671.5 million

 Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of approx. SEK 671.5 million before transaction costs.
October 03, 2025